Tumor type: Lymphoma
Purpose of Study: The purpose of this study is to evaluate the safety and antitumor activity of KPT-335 in dogs with lymphoma, either newly diagnosed or in first relapse after completion of a single chemotherapy protocol (multi-agent or single agent).
A study of KPT-335 was performed in dogs with cancer and the dose of 1.5 mg/kg was found to be well-tolerated over 4-20 weeks of dosing when given on a Monday/Wednesday/Friday (MWF) basis. In dogs with lymphoma, partial shrinkage of lymph nodes and stable disease were noted in over half of the patients treated. Side effects from KPT-335 given at this dose on a MWF basis included mild loss of appetite, occasional vomiting, and diarrhea, with some dogs experiencing an increase in thirst and an increase in urination. All of these side effect were mild and well-controlled with additional medications. For more information, click here.